Co-Development Agreements

The National Cancer Institute's Technology Transfer Center (TTC) recognizes the importance of co-development in order to translate early-stage discoveries to outside entities to benefit public health. In support of this goal, the TTC establishes formal collaborative agreements with industry, academia, and non-profits to facilitate co-development through the exchange and development of research materials, knowledge, and technologies.

The TTC uses three different co-development agreements to help industry and academia interact and partner with National Institutes of Health laboratories and scientists to support technology development activities:

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Purpose</th>
<th>Essential Elements</th>
</tr>
</thead>
</table>
| Collaboration Agreement (CA)      | Permits a two-way exchange of materials and information, and assumes exchange of results and/or conclusions will occur between NIH and companies, universities, state/local governments, Federal labs, and non-profits.                                                                 | - Combines terms of a CDA and MTA  
- Simplified research plan  
- Exchange of new material created during the collaboration is addressed  
- No funding from the outside party allowed  
- No license option  
- Rights to foreground IP are not addressed  
- Human and non-human materials covered  |
<table>
<thead>
<tr>
<th>Agreements</th>
<th>Purpose</th>
<th>Essential Elements</th>
</tr>
</thead>
</table>
| Cooperative Research and Development Agreement (CRADA) | Permits co-development of NIH or outside invention involving companies, universities, state/local governments, Federal labs, and non-profits. | For NIH:  
- May receive funds or in-kind contributions for collaborative research project  
- May provide confidentiality for research results up to five years after development  

For Collaborator:  
- Option to exclusively license any inventions that are developed by a Federal laboratory employee(s) as part of the collaborative research  
- Access to unique reagents and resources  
- Access to scientific and regulatory expertise  
- Access to Federal lab  

- Covers investigational data, drug, diagnostic, or device  
- No funding from the outside party required  
- No option to license foreground IP  
- Clinical and non-clinical  
- Addresses regulatory issues and monitoring  
- Addresses Personally Identifiable Information (PII) |
| Clinical Trial Agreement (CTA) | Transfers material into NIH for research in Human Subjects from companies, state/local governments, non-profits, universities | |

**Updated**  
Monday, December 18, 2017

**Source URL:** https://techtransfer.cancer.gov/partnering-with-nih/co-development-agreements